Anacor Pharmaceuticals Inc  

(Public, NASDAQ:ANAC)   Watch this stock  
Jun 23 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 52.00 - 156.93
Open     -
Vol / Avg. 0.00/4.02M
Mkt cap 4.50B
P/E     -
Div/yield     -
EPS -1.45
Shares 45.37M
Beta 1.53
Inst. own 106%

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin -92.08% -74.37%
Operating margin -85.09% -68.43%
EBITD margin - -67.69%
Return on average assets -38.09% -32.07%
Return on average equity -133.71% -93.42%
Employees 110 -
CDP Score - -


1020 E Meadow Cir
PALO ALTO, CA 94303-4230
United States - Map
+1-650-5437500 (Phone)
+1-650-5437660 (Fax)

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Anacor Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing small-molecule therapeutics derived from its boron chemistry platform. Its lead product development candidate is crisaborole topical ointment, approximately 2%, a non-steroidal topical anti-inflammatory phosphodiesterase-4 (PDE-4) inhibitor in development for the treatment of mild-to-moderate atopic dermatitis and psoriasis. Its product, KERYDIN (tavaborole) topical solution, approximately 5%, is an oxaborole antifungal approved by the United States Food and Drug Administration (FDA) for the topical treatment of onychomycosis of the toenails. It also has a pipeline of other internally discovered topical and systemic boron-based compounds in early-stages of research and development, which include AN3365. Its compound, AN5568 (SCYX-7158), is licensed to Drugs for Neglected Diseases initiative (DNDi) for the treatment of human African trypanosomiasis.